InvestDashboard.com



Nektar Therapeutics (NKTR)



$11.41
52 Week Low
$18.97
2017-04-28 15:17:56 MDT
$24.88
52 Week High

Basic Info

Healthcare
Sector
Biotechnology
Industry
Nasdaq
Stock Exchange
United States
Country

Market Cap: $2,900,000,000Mid Cap (Between $2B and $10B)
Analyst Recommendation:1.6Analysts say: Buy+. (1=Strong Buy, 5=Strong Sell)
Beta: 2.31 Higher Volatility Stock (beta over 1). Stock will go up more when the market goes up, and go down more when the market goes down. Beta of 1 means stock would match the S&P 500 Index.

Fundamentals

ForwardPE: Unknown
5 Yr Est Growth: -7.30 %
Yield: 0.00%
PEG-Y Ratio: N/A
Unknown PEG-Y ratio

Technicals

% Above 50 DayMA: -1.81%
% Above 200 DayMA: 28.44%
NKTR Performance 52 Weeks: 16.85%
S&P 500 Performance 52 Weeks: 13.50%
Mixed Trend. Short Term trend is down, but longer term trend is up. There is hope because 50 Day MA is still above 200 Day MA. Stock is closer to 52 Week High than 52 Week Low.
NKTR outperforming S&P 500 by 3.35% the last 52 Weeks.

Profile


More Valuation

Price To Book: 31.95
Not so great value. Low Price to Book means better value. A P/B value of 5 or less is great. But consider other metrics and maybe the growth and yield makes it worth it.
EV to EBITDA: -27.54
Unknown EV to EBITDA ratio

More Info

Field Value Average Comments
% Held By Insiders0.44% 17.28%Held by fewer than average Insiders.
% Held By Institutions105.70% 62.07%Institutional percentage greater than average. Institutional buying and selling can really move stock price.
Short % Of Float12.58% 07.02% Shorted by greater than average percent. Investors and traders do not believe in stock. But watch out for short squeezes pushing stock upwards.
Debt to Equity2.82 1.08 More Aggressive Financing. Each industry has different Debt/Equity standard. Higher than 1 means company is taking on more leverage.
Profit Margin %-92.80%-00.18% Profit Margin is less than average.
Operating Margin %-68.22%-05.28% Operating Margin less than average percent. Stock can do better than this?
Return on Equity %-324.73%-08.79% Return on Equity less than average percent. Stock can do better than this?
Return on Assets %-13.22%-01.29% Return on Assets less than average percent. Stock can do better than this?
Revenue Per Employee $353,504.27 $883,096.70 Less than average Revenue Per Employee. This stock (or industry) might not be as efficient as others? Each industry might have a different standard.
Price to Cash 7.50 5.52 Higher than average Price to Cash. Meaning that the company has a lower percentage of cash as a percent of price. Cash can be good to cushion company during hard times, and as a potential source for buyouts or investments. However, some activists want the cash to be used by a company to buy its own stock, or to increase their dividend, or to invest the money.
CPEGY Ratio N/A 2.26Unknown.

Quick Thoughts

PROS:
  1. Analysts like this stock: 1.6 (1=Strong Buy, 5=Strong Sell)

  2. Stock is Above Long Term 200DMA: 28.44%

  3. Stock outperforming S&P 500 over last 52 weeks: 3.35%

CONS:
  1. Less than Average 5 Yr Est Growth: -7.30 %

  2. Stock is Below Short Term 50DMA: -1.81%

  3. Price to Cash Ratio (7.50) is greater than average. Company has less cash as a percent of price than the average.

  4. Price to Book is over 10: 31.95

  5. Shorted more than average: 12.58%

  6. Profit Margin is negative: -92.80%

  7. Operating Margin is negative: -68.22%

  8. Return on Equity is negative: -324.73%

  9. Return on Assets is negative: -13.22%

  10. Debt To Equity is greater than 2. But might be industry standard? 2.82


Headlines


Stock Chart


InvestDashboard.com NKTR: Nektar Therapeutics

This page updated Thu Feb 1 22:00:01 MST 2018.